BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 5, 2026
$8,17
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$6,0052 haftanın en düşüğü
$11,2252 haftanın en yükseği
Piyasa Değeri (MRQ)
$2.09B
P/E (TTM)
-5.5
Hisse Başına Kâr (TTM)
$-1.49
Gelir (TTM)
$941M
rozetleriniz
52 Haftlık Aralık
$6–$11
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$21
P/E
-5.5
ROE
87.8%
Net Kâr Marjı
-40.9%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
BCRX Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$8.17
Piyasa Değeri (MRQ)
$2.09B
P/E (TTM)
-5.5
Hisse Başına Kâr (TTM)
$-1.49
Gelir (TTM)
$941M
ROE (TTM)
87.8%
D/E Borç/Özsermaye (MRQ)
-0.9
52 Haftlık Aralık
$6–$11
BCRX Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
BioCryst Pharmaceuticals, Inc. - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriBiotechnology
çalışanlar435
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$875M2016-12-31 → 2025-12-31
Hisse Başına Kâr$1.212020-12-31 → 2025-12-31
Serbest Nakit Akışı$345M2016-12-31 → 2025-12-31
Net kar marjı-40.9%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | BCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -5.55Y ort. ≈-7.6 | ≈-7.6 | · | · | |
| F/S (TTM) | 2.25Y ort. ≈6.7 | ≈6.7 | 29.2 | Düşük değerli | |
| F/D (MRQ) | -4.65Y ort. ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA | 5.35Y ort. ≈-281.5 | ≈-281.5 | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | 5.65Y ort. ≈-13.6 | ≈-13.6 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 5.55Y ort. ≈-13.9 | ≈-13.9 | · | · | |
| EV / Gelir (TTM) | 2.35Y ort. ≈6.3 | ≈6.3 | · | · | |
| EV / FCF (TTM) | 5.75Y ort. ≈-14.4 | ≈-14.4 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | BCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -33.3%5Y ort. ≈-32.2% | ≈-32.2% | -1041.7% | En üst düzey | |
| EBITDA Margin (FAVÖK Marjı) | 39.1%5Y ort. ≈-31.8% | ≈-31.8% | -1041.7% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | -40.5%5Y ort. ≈-52.6% | ≈-52.6% | -493.4% | En üst düzey | |
| Net Kâr Marjı (TTM) | -40.9%5Y ort. ≈-53.3% | ≈-53.3% | -990.1% | En üst düzey | |
| ROA (TTM) | -75.8%5Y ort. ≈-18.2% | ≈-18.2% | -40.3% | En üst düzey | |
| ROE (TTM) | 87.8%5Y ort. ≈42.1% | ≈42.1% | -55.6% | Zayıf | |
| ROIC | -282.4%5Y ort. ≈-118.5% | ≈-118.5% | -55.2% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | BCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | -0.95Y ort. ≈-0.7 | ≈-0.7 | 0.0 | Düşük borç | |
| Cari Oran (MRQ) | 2.35Y ort. ≈3.7 | ≈3.7 | 6.7 | Düşük likidite | |
| Cari Oran (MRQ) | 2.25Y ort. ≈2.5 | ≈2.5 | 4.5 | Düşük likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | -0.95Y ort. ≈-0.7 | ≈-0.7 | 0.2 | Düşük borç |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | BCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 94.1%5Y ort. ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 47.8%5Y ort. ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 117.9% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | BCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 1.75Y ort. ≈0.8 | ≈0.8 | 0.1 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 2.85Y ort. ≈0.9 | ≈0.9 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 9.45Y ort. ≈7.4 | ≈7.4 | · | · | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$2.0M | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
23.2%
Sonraki Rapor
Kas 02, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 3, 2026 | $0.30 | $0.12 | 148.1% |
| 31 Mart 2026 | $-0.09 | $0.05 | -281.8% | |
| 31 Aralık 2025 | $0.01 | $0.04 | -74.1% | |
| 30 Eylül 2025 | $0.06 | $0.04 | 67.1% | |
| 30 Haziran 2025 | $0.04 | $0.01 | 179.7% | |
| 31 Mart 2025 | $0.00 | $-0.07 | 100.0% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $875M | $451M | $331M | $271M | $157M |
| Faaliyet Kâr Marjı % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Net Gelir | $264M | $-89M | $-227M | $-247M | $-184M |
| Seyreltilmiş Hisse Başı Kâr | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Cari Oran | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Cari Oran | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $345M | $-53M | $-97M | $-163M | $-145M |
Kurumsal Sahipler (13F) 345 dosya · $2.8B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
345
Tutulan Değer
$2.8B
Yeni pozisyonlar
55
Çıkan pozisyonlar
34
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 55 (-22 önceki Ç'ye göre) | 34 (-5 önceki Ç'ye göre) | 137 (+20 önceki Ç'ye göre) | 87 (+8 önceki Ç'ye göre) | +4.1M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $238.930.360 | 23.893.036 | 8,46% | Hisse senetleri |
| VANGUARD GROUP INC | $173.732.325 | 22.273.375 | 6,15% | Hisse senetleri |
| RA CAPITAL MANAGEMENT, L.P. | $158.271.860 | 15.827.186 | 5,61% | Hisse senetleri |
| STATE STREET CORP | $151.910.980 | 15.191.098 | 5,38% | Hisse senetleri |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150.964.030 | 15.096.403 | 5,35% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $113.642.360 | 11.364.236 | 4,03% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111.391.580 | 11.139.158 | 3,95% | Hisse senetleri |
| TCG Crossover Management, LLC | $110.209.680 | 11.020.968 | 3,90% | Hisse senetleri |
| PERCEPTIVE ADVISORS LLC | $103.088.880 | 10.308.888 | 3,65% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $84.853.520 | 8.908.506 | 3,01% | Hisse senetleri |
| Vestal Point Capital, LP | $83.000.000 | 8.300.000 | 2,94% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $67.753.490 | 6.775.349 | 2,40% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $62.493.232 | 6.248.046 | 2,21% | Hisse senetleri |
| Aberdeen Group plc | $53.108.710 | 5.310.871 | 1,88% | Hisse senetleri |
| UBS Group AG | $50.782.800 | 5.078.280 | 1,80% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $48.012.840 | 4.801.284 | 1,70% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $44.818.738 | 4.481.874 | 1,59% | Hisse senetleri |
| Frazier Life Sciences Management, L.P. | $40.092.400 | 4.009.240 | 1,42% | Hisse senetleri |
| Nuveen, LLC | $40.072.370 | 4.007.237 | 1,42% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $33.947.290 | 3.394.729 | 1,20% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $31.895.074 | 4.089.112 | 1,13% | Hisse senetleri |
| RP Management, LLC | $28.846.155 | 3.846.154 | 1,02% | Hisse senetleri |
| JANE STREET GROUP, LLC | $27.626.830 | 2.762.683 | 0,98% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $27.187.810 | 2.718.781 | 0,96% | Hisse senetleri |
| Fisher Asset Management, LLC | $26.040.270 | 2.604.027 | 0,92% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $25.302.900 | 2.530.290 | 0,90% | Hisse senetleri |
| Kynam Capital Management, LP | $25.226.600 | 2.522.660 | 0,89% | Hisse senetleri |
| Candriam S.C.A. | $25.125.293 | 2.514.949 | 0,89% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23.532.910 | 2.353.291 | 0,83% | Hisse senetleri |
| RICE HALL JAMES & ASSOCIATES, LLC | $23.320.430 | 2.332.043 | 0,83% | Hisse senetleri |
| NORTHERN TRUST CORP | $22.557.310 | 2.255.731 | 0,80% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $22.143.020 | 2.214.302 | 0,78% | Hisse senetleri |
| MORGAN STANLEY | $19.996.852 | 1.999.684 | 0,71% | Hisse senetleri |
| Nantahala Capital Management, LLC | $19.011.600 | 1.901.160 | 0,67% | Hisse senetleri |
| Eversept Partners, LP | $18.656.530 | 1.865.653 | 0,66% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $18.520.000 | 1.852.000 | 0,66% | Hisse senetleri |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18.449.120 | 1.844.912 | 0,65% | Hisse senetleri |
| STIFEL FINANCIAL CORP | $18.262.340 | 1.826.234 | 0,65% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $17.595.730 | 1.759.573 | 0,62% | Hisse senetleri |
| CITADEL ADVISORS LLC | $17.591.600 | 1.759.160 | 0,62% | Hisse senetleri |
| JUPITER ASSET MANAGEMENT LTD | $16.428.740 | 1.642.874 | 0,58% | Hisse senetleri |
| IMC-Chicago, LLC | $16.343.360 | 1.634.336 | 0,58% | Hisse senetleri |
| Parkman Healthcare Partners LLC | $16.242.790 | 1.624.279 | 0,58% | Hisse senetleri |
| Legal & General Group Plc | $14.555.141 | 1.455.514 | 0,52% | Hisse senetleri |
| OP Asset Management Ltd | $13.409.900 | 1.340.990 | 0,48% | Hisse senetleri |
| Invesco Ltd. | $12.337.830 | 1.233.783 | 0,44% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11.956.510 | 1.195.651 | 0,42% | Hisse senetleri |
| Pictet Asset Management Holding SA | $11.951.392 | 1.249.771 | 0,42% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $11.740.520 | 1.174.052 | 0,42% | Hisse senetleri |
| FIRST TRUST ADVISORS LP | $11.204.690 | 1.120.469 | 0,40% | Hisse senetleri |
Aktivistler ve %5+ sahipler 15 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 başvurular | 31 Temmuz 2018 | · | İlk başvuru | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 02 Nisan 2018 | · | İlk başvuru | Pasif yatırım | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 başvurular | 16 Ağustos 2016 | · | İlk başvuru | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 başvurular | 23 Ekim 2012 | · | İlk başvuru | M&A / satış | SEC |
| Julian C. Baker, Felix J. Baker ×4 başvurular | 13 Ekim 2011 | · | İlk başvuru | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 başvurular | 20 Ağustos 2007 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 07 Aralık 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 07 Aralık 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 07 Aralık 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 13 Ekim 2005 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 26 Şubat 2004 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 25 Şubat 2004 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 24 Şubat 2004 | · | İlk başvuru | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 başvurular | 31 Ekim 2003 | · | İlk başvuru | · | SEC |
| William W. Featheringill | 14 Şubat 2002 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 51 içeriden öğrenenler · 21 yöneticiler · 30 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 Aralık 2025 A | 268.700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 Aralık 2024 A | 377.867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 Şubat 2020 A | 125.176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 Mart 2011 M | 57.102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 Aralık 2025 M | 952.583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 Mart 2008 A | 65.730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 Mayıs 2026 M | 400.703 | 0 | 7 | $-3.461.969 |
| Sandeep Menon | Chief R&D Officer | 06 Nisan 2026 A | 205.150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 Mart 2025 F | 377.318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 Aralık 2022 A | 16.653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 Kasım 2022 M | 298.541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 Mart 2022 M | 37.954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 Aralık 2020 A | 45.000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 Ocak 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 Mart 2012 F | 24.124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 07 Şubat 2011 A | 9.766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 Mart 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 Temmuz 2008 P | 3.048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 Temmuz 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 Temmuz 2007 P | 3.659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 Mayıs 2007 A | 1.928 | 0 | 0 | $0 |
| Amy E Mckee | Yönetim kurulu üyesi | 31 Ağustos 2026 A | 47.821 | 0 | 1 | $-100.285 |
| Jill C. Milne | Yönetim kurulu üyesi | 31 Ağustos 2026 A | 33.226 | 0 | 0 | $0 |
| Steven Frank | Yönetim kurulu üyesi | 31 Ağustos 2026 A | 36.747 | 0 | 0 | $0 |
| Jon P Stonehouse | Yönetim kurulu üyesi | 31 Ağustos 2026 A | 1.340.419 | 0 | 0 | $0 |
| Vincent Milano | Yönetim kurulu üyesi | 31 Ağustos 2026 A | 109.642 | 0 | 0 | $0 |
| Theresa Heggie | Yönetim kurulu üyesi | 11 Haziran 2026 A | 80.646 | 0 | 1 | $-504.823 |
| Machelle Sanders | Yönetim kurulu üyesi | 11 Haziran 2026 A | 45.936 | 0 | 1 | $-68.544 |
| Steven K Galson | Yönetim kurulu üyesi | 11 Haziran 2026 A | 27.794 | 0 | 0 | $0 |
| Alan G Levin | Yönetim kurulu üyesi | 11 Haziran 2026 A | 79.565 | 0 | 0 | $0 |
| Nancy J Hutson | Yönetim kurulu üyesi | 12 Haziran 2025 A | 99.138 | 0 | 0 | $0 |
| George B Abercrombie | Yönetim kurulu üyesi | 12 Haziran 2024 A | 36.431 | 0 | 0 | $0 |
| Steve Aselage | Yönetim kurulu üyesi | 12 Haziran 2024 A | 70.159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Yönetim kurulu üyesi | 13 Haziran 2023 A | 68.863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Yönetim kurulu üyesi | 28 Şubat 2023 A | 100.198 | 0 | 0 | $0 |
| Stanley C Erck | Yönetim kurulu üyesi | 28 Kasım 2018 M | 48.333 | 0 | 0 | $0 |
| Fred Cohen | Yönetim kurulu üyesi | 20 Haziran 2018 A | 119.410 | 0 | 0 | $0 |
| Sanj K Patel | Yönetim kurulu üyesi | 24 Mayıs 2017 A | · | 0 | 0 | $0 |
| Charles A Sanders | Yönetim kurulu üyesi | 29 Şubat 2016 A | 12.971 | 0 | 0 | $0 |
| Peder Jensen | Yönetim kurulu üyesi | 02 Mayıs 2014 A | 60.000 | 0 | 0 | $0 |
| John L Higgins | Yönetim kurulu üyesi | 23 Mayıs 2012 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Yönetim kurulu üyesi | 23 Mayıs 2012 A | 3.000 | 0 | 0 | $0 |
| Stephen R Biggar | Yönetim kurulu üyesi | 12 Mayıs 2011 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | Yönetim kurulu üyesi | 13 Mayıs 2010 A | 3.000 | 0 | 0 | $0 |
| William W Featheringill | Yönetim kurulu üyesi | 13 Mayıs 2010 A | 231.538 | 0 | 0 | $0 |
| William M Spencer III | Yönetim kurulu üyesi | 16 Mayıs 2007 A | 186.761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Yönetim kurulu üyesi | 16 Mayıs 2007 A | 451.900 | 0 | 0 | $0 |
| Charles E Bugg | Yönetim kurulu üyesi | 18 Mart 2007 A | 62.439 | 0 | 0 | $0 |
| GORDON CARL L | Yönetim kurulu üyesi | 17 Mayıs 2006 A | 1.100.000 | 0 | 0 | $0 |
| John A Montgomery | Yönetim kurulu üyesi | 04 Kasım 2003 M | 46.785 | 0 | 0 | $0 |
| Randolph C Steer | · | 21 Mayıs 2008 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 41 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,35% | 1.193.733 SH | 01 Ekim 2026 | Günlük |
| BBP · ETFis Series Trust I | 1,42% | 155.993 NS | 31 Temmuz 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0,99% | 510 NS | 31 Temmuz 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,92% | 1.078.429 NS | 31 Temmuz 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 248.560 NS | 31 Temmuz 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,59% | 324.702 NS | 31 Temmuz 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,36% | 516.595 NS | 31 Temmuz 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,23% | 73.039 SH | 01 Ekim 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,17% | 4.436 NS | 31 Temmuz 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249.665 SH | 19 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,14% | 18.119 SH | 01 Ekim 2026 | Günlük |
| ESSC · Strategy Shares | 0,14% | 5.593 NS | 31 Temmuz 2026 | N-PORT |
| IBB · iShares Trust | 0,13% | 1.651.139 SH | 11 Eylül 2026 | Günlük |
| IWO · iShares Trust | 0,13% | 2.178.966 SH | 11 Eylül 2026 | Günlük |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 174.467 NS | 31 Temmuz 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 64.429 NS | 31 Temmuz 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 46.799 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1.339.774 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,07% | 111.471 NS | 31 Temmuz 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 75.067 SH | 11 Eylül 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,06% | 207.179 SH | 01 Ekim 2026 | Günlük |
| IWM · iShares Trust | 0,06% | 5.937.121 SH | 11 Eylül 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,05% | 770.732 NS | 31 Temmuz 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1.696.014 SH | 19 Ağustos 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.837.341 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,03% | 624.412 SH | 19 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 99.007 NS | 31 Temmuz 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.922.024 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,01% | 11.812 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 72.998 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 336.323 SH | 11 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 52.194 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36.571 NS | 31 Temmuz 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 286 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8.070.274 SH | 19 Ağustos 2026 | Günlük |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 196.622 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 19.676 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,00% | 51.624 SH | 19 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 10.494 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 766.086 SH | 11 Eylül 2026 | Günlük |
BCRX Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 17 analist
AL
Medyan hedef
$17.00
+108,1%
5 29,4%
Güçlü Al
10 58,8%
Al
2 11,8%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
11 analist · 2026-09-28Ortalama hedef $20.64 +152,6%
← Tüm hedeflerin altında
Mevcut fiyat $8.17
Düşük$11.00
Ortalama$20.64
Yüksek$32.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
Son Haberler Bu şirketten bahseden son manşetler
RBC Capital, BioCryst Pharmaceuticals (BCRX) için Fiyat Hedefini Yükseltti, Biyoteknoloji Alanındaki 1. Çeyrek 2026 Sonuçları Ön İzlemesi Kapsamında
Yahoo Finance · 5 ay önce
BioCryst (BCRX) 7.10% Yükselişe Erişiyor, Edinme Söylentileriyle
Yahoo Finance · 6 ay, 1 hafta önce
BioCryst Pharmaceuticals, Inc. (BCRX) Şimdi Alınacak İyi Bir Hisse mi?
Yahoo Finance · 6 ay, 1 hafta önce
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 5, 2026